Jamie Dananberg Sells 5,521 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) insider Jamie Dananberg sold 5,521 shares of Annexon stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $2.96, for a total value of $16,342.16. Following the sale, the insider now owns 33,479 shares of the company’s stock, valued at approximately $99,097.84. This represents a 14.16 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Annexon Price Performance

Shares of ANNX stock opened at $2.81 on Friday. The firm’s 50-day simple moving average is $4.26 and its 200-day simple moving average is $5.55. Annexon, Inc. has a 1-year low of $2.63 and a 1-year high of $8.40. The firm has a market cap of $299.52 million, a P/E ratio of -2.68 and a beta of 1.07.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Annexon has a consensus rating of “Buy” and a consensus target price of $15.80.

Hedge Funds Weigh In On Annexon

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Parkman Healthcare Partners LLC boosted its holdings in shares of Annexon by 0.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company’s stock valued at $1,945,000 after purchasing an additional 1,768 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Annexon by 1.6% in the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company’s stock valued at $945,000 after acquiring an additional 2,450 shares during the last quarter. GSA Capital Partners LLP grew its position in Annexon by 10.7% during the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after acquiring an additional 3,355 shares during the period. E Fund Management Co. Ltd. increased its stake in Annexon by 36.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock worth $79,000 after acquiring an additional 4,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Annexon by 6.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company’s stock worth $325,000 after purchasing an additional 4,092 shares during the period.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.